对于晚期肝细胞癌的杜尔瓦卢马布-卡博赞提尼布连续治疗完全缓解的病例
Masaki Ogami1, Hironao Okubo2, Ryuji Yoshioka3
1Department of Gastroenterology, Juntendo University Nerima Hospital, 3-1-10 Takanodai, Nerima-Ku, Tokyo, 177-8521, Japan.
在其他治疗失败后,卡博桑提尼布在患有晚期肝细胞癌 (HCC) 的患者中实现了显著的完全缓解. 这种氨酸激酶抑制剂为难以治疗的HCC病例提供了潜在的新选择.
科学领域:
- 在瘤学瘤学.
- 医学科学 医学科学 医学科学
背景情况:
- 肝细胞癌 (HCC) 是一种具有不良预后的原发性肝癌.
- 先进的HCC通常需要多线系统疗法.
- 在HCC中完全缓解是罕见的,特别是在后期治疗.
研究的目的:
- 报告一个在晚期肝细胞癌中对卡博赞提尼布显著反应的病例.
- 突出卡博赞提尼布作为潜在的后期治疗不可切除的HCC.
主要方法:
- 一名57岁的女性患有晚期HCC和肺转移,此前接受过多次治疗.
- 治疗包括阿特佐利祖马布加贝瓦齐祖马布,其次是伦瓦替尼.
- 卡博赞提尼布在疾病进展后开始作为后期治疗.
主要成果:
- 患者通过卡博桑提尼布获得了显著的反应,在12周后,阿尔法-胎蛋白水平正常化.
- 计算机断层扫描显示只有轻微的痕状的肺结节.
- 患者在停止卡博赞提尼布治疗12个月后仍然没有癌症,卡博赞提尼布治疗持续了11个月.
结论:
- 卡博桑提尼布可以在晚期肝细胞癌中诱导完全和持久的缓解.
- 这一案例表明,卡博赞提尼布是不可切除的HCC的可行和有效的后期治疗选择.
- 需要进一步研究卡博赞提尼布在晚期HCC的疗效.
更多相关视频
09:49Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
Published on: December 2, 2013
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
相关概念视频
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Chronic Pancreatitis II: Collaborative Care
Assessment:
